This is a phase II precision medicine cancer trial with nearly 40 treatment arms. See study details. Patients with advanced solid tumors, lymphomas, or myeloma may be eligible, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment. Some arms have exceptions. Each arm targets a unique gene abnormality known to drive cancer growth. Many of these driver mutations occur only rarely in patients, as shown by the posted frequency rates. These are the rates found in the first 6,000 patients tested in this trial. See the table below for the open treatment arms.
Total accrual: 1197 as of 02/19/2022
http://ecog-acrin.org/trials/nci-match-eay131
For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Email: cancer@cchmc.org
|
TARGET
|
STUDY / ID
|
ACCRUAL
|
AGENT
|
DISEASE EXCEPTIONS
|
DATE ACTIVATED
|
STATUS
|
|
BRAF V600E or V600K mutations
(0.69% frequency)
|
H
|
50 (5)
|
Taflinar® (dabrafenib) and Mekinist™ (trametinib)
|
Colorectal cancer, melanoma, non-small cell lung cancer, or thyroid cancer
|
10/02/2020
|
OPEN
|
|
LAG-3 expression with MMR deficiency
(1.51% frequency)
|
Z1M
|
35 (0)
|
relatlimab + Opdivo® (nivolumab)
|
Active melanoma
|
04/19/2021
|
OPEN
|